Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — ØU Life Science Investor Konference 2023
22 slides from Expres2ion Biotech Holding Ab's conference presentation, Apr 19, 2023
Slide 1: Proteins for Life
19th April 2023 ØU Life Science Investor Konference Proteins for Life ExpreS2ion Biotech Holding AB [NASDAQ First North Growth Market: EXPRS2] – a clinical Phase III development stage vaccine company Bent U. Frandsen, CEO
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Investment Highlights
Investment Highlights We turn complex proteins into tomorrow’s vaccines High-potential pipeline of key focus within infections diseases and oncology, backed up by strong intellectual property rights. Targeting sizeable unmet medical needs and markets Vaccine development platform with strong track re
Slide 4: Unique Technology Platforms
Unique Technology Platforms Combines a highly immunogenic antigen with unique presentation technology Particle (VLP) technology ExpreS2 platform - AdaptVac’s proprietary virus- - Combines S2 cells with like particles (VLP) technology patented expression vectors securely attaches our proteins (add a
Slide 5: Broad Clinical Stage Vaccine Pipeline
Broad Clinical Stage Vaccine Pipeline Development Progress Market Target Pre-clinical Potential DISEASE Project/Target ID cGMP / Tox Phase I Phase II Phase III Partner/Funding Identification Pharmacology >€30 billion1 COVID-19 ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II 100% >€10 billion2
Slide 6: Breast Cancer
BREAST CANCER Breast Cancer - The Most Common Cancer 1 in 8 women will be diagnosed with invasive breast cancer in her lifetime ~25% are HER2-positive, which is associated with more aggressive tumors and reduced survival. 685,000 deaths worldwide in 2020 due to breast cancer1 Global market size expe
Slide 7: Current Breast Cancer treatments
BREAST CANCER Current Breast Cancer treatments The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Existing therapies Significant drawbacks exist with existing therapies2 Monoclonal antibodies are the cornerstone of treatment for HER2+ breast cancer (>USD 11bn
Slide 8: ES2B-C001 Preclinical Proof-of-Concept
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept ES2B-C001 has demonstrated animal proof-of-concept Effectively inhibited tumor development Prevented tumor development with 95% efficiency Tumor growth in FVB mice Kaplan-Meier survival curves (HER2-intolerant) ****p<0.0001 by the log-rank test ES
Slide 9: Publication Supports ES2B-C001
BREAST CANCER Publication Supports ES2B-C001 Pre-clinical proof of concept • Vaccines are a promising therapeutic alternative to monoclonal antibodies against HER-2+ breast cancer. • Polyclonal antibodies generated after vaccination with ES2B-C001 inhibited growth of human HER-2+ trastuzumab-resista
Slide 10: Progression as Planned
BREAST CANCER Progression as Planned Important steps as ES2B-C001 is moving closer to the planned clinical Phase I trial in 2024 GMP Manufacturing Preclinical Safety ✓ GMP (Good Manufacturing Practice) Manufacturers selected and ✓ GLP (Good Laboratory Practice) CRO (Contract Research Work Order Stat
Slide 11: Oncology Scientific Advisory Board
BREAST CANCER Oncology Scientific Advisory Board Key Opinion Leaders (KOLs) providing clinical advice on our oncology development programme Dr. Giuseppe Curigliano, MD, PhD Dr. Ulrik Lassen, MD, PhD Associate Professor of Medical Oncology at the University of Milano and the Professor at University o
Slide 12: The 2nd Generation COVID-19 Vaccine
COVID-19 nd The 2 Generation COVID-19 Vaccine With ~7 million deaths worldwide1, significant needs remain in the global long-term fight against the SARS-CoV-2 virus: Uncertain duration of effect with current vaccines, expected to need repeated boosters Storage and handling requirements for many vacc
Slide 13: Publication Supports ABNCoV2 Vaccine
COVID-19 Publication Supports ABNCoV2 Vaccine Phase I clinical trial findings Published January 18, • 45 participants (six to nine per group) were enrolled between 2023 March 15 and July 15, 2021. Participants had a total of 249 at least possibly related solicited adverse events (185 grade 1, 63 gra
Slide 14: ABNCoV2 COVID-19 Vaccine
COVID-19 ABNCoV2 COVID-19 Vaccine1 Successful completion of Phase II study, and on-going Phase III study since Q3 2022 Phase II: Safe & highly efficacious against SARS-CoV-2 Phase III: Initiation of pivotal study in Q3 2022 • Favorable safety profile: Vaccine was generally well-tolerated, with no re
Slide 15: Partnership with Bavarian Nordic
COVID-19 Partnership with Bavarian Nordic ABNCoV2 is out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receives from Bavarian Nordic ExpreS2ion receives from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in developme
Slide 16: CMV - A Very Common Infection
INFLUENZA / CYTOMEGALO- MALARIA VIRUS (CMV) CMV - A Very Common Infection 1 in 3 children is already infected with CMV by age 5 >50% of US adults are infected with the virus by age 401 adults and children receiving 1 in 5 organ transplants (kidney, liver, lung, heart, stem-cells) are at risk of CMV
Slide 17: Uniting Forces in CMV Vaccine Research
INFLUENZA / CYTOMEGALO- MALARIA VIRUS (CMV) Uniting Forces in CMV Vaccine Research ExpreS2ion and Evaxion Biotech new vaccine research partnership since December 2022 • Vaccine Discovery Collaboration Agreement announced Dec. 6th, 2022 • Research partnership with focus on discovery and development o
Slide 18: New Scientific Advisory Board
INFLUENZA / CYTOMEGALO- MALARIA VIRUS (CMV) New Scientific Advisory Board KOLs providing scientific advice on our infectious diseases' development programmes Dr. Stanley Plotkin, MD, PhD, DMSci Dr. Allan Randrup Thomsen, MD, DMSci Dr. Stanley Plotkin serves as a consultant to the vaccine industry an
Slide 19: Financials and Outlook
Financials and Outlook Proteins for Life
Slide 20: Financials – Fitting the Pipeline Strategy
FINANCE Financials – Fitting the Pipeline Strategy Q1-Q2 2023 rights issue flows in approximately 54 MSEK in gross proceeds Revenues, SEK ‘000s Operating profit/loss, SEK ‘000s Cash balance, SEK million 6.000 180 Net sales Other operating income 168 0 160 5.000 150 142 139 -8.000 140 125 4.000 120 -
Slide 21: Advancing Towards Key Catalysts
Advancing Towards Key Catalysts 2022 2023 2024 2025 COVID-19 (ABNCoV2) BN Phase III initial readout BN Phase II BN Phase III BN initiating rolling submission study readout study initiation Royalties from sales? BN ready for market launch H1 2022 Q3 2022 (subject to regulatory approval) BREAST CANCER
Slide 22: Proteins for Life
Thank you! www.expreS2ionbio.com Proteins for Life
ExpreS2ion Biotech Holding — ØU Life Science Investor Konference 2023 on 6ix